SCTR | Secretin receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SDCBP2 | Syndecan binding protein (syntenin) 2 | | | | | | Tissue enhanced |
SH2D6 | SH2 domain containing 6 | | | | | | Tissue enhanced |
SH2D7 | SH2 domain containing 7 | | | | | | Tissue enhanced |
SLC22A18 | Solute carrier family 22, member 18 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC25A34 | Solute carrier family 25, member 34 | Mitochondrial proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC28A2 | Solute carrier family 28 (concentrative nucleoside transporter), member 2 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC2A5 | Solute carrier family 2 (facilitated glucose/fructose transporter), member 5 | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
SLC30A10 | Solute carrier family 30, member 10 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC51B | Solute carrier family 51, beta subunit | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC6A20 | Solute carrier family 6 (proline IMINO transporter), member 20 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SMPD3 | Sphingomyelin phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II) | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
SOWAHA | Sosondowah ankyrin repeat domain family member A | Predicted secreted proteins
| | | | | Tissue enhanced |
SULT1C3 | Sulfotransferase family, cytosolic, 1C, member 3 | Enzymes
| | | | | Tissue enhanced |
TLX2 | T-cell leukemia homeobox 2 | Transcription factors
| | | | | Tissue enhanced |
TM4SF5 | Transmembrane 4 L six family member 5 | Predicted membrane proteins
| | | | | Tissue enhanced |
TM6SF2 | Transmembrane 6 superfamily member 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
TMEM150B | Transmembrane protein 150B | Predicted membrane proteins
| | | | | Tissue enhanced |
TMEM229A | Transmembrane protein 229A | Predicted membrane proteins
| | | | | Tissue enhanced |
TMEM45B | Transmembrane protein 45B | Predicted membrane proteins
| | | | | Tissue enhanced |
TNFRSF11A | Tumor necrosis factor receptor superfamily, member 11a, NFKB activator | CD markers Disease related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
TRIM15 | Tripartite motif containing 15 | | | | | | Tissue enhanced |
TRIM40 | Tripartite motif containing 40 | | | | | | Tissue enhanced |
TRPC7 | Transient receptor potential cation channel, subfamily C, member 7 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
TRPM5 | Transient receptor potential cation channel, subfamily M, member 5 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
TSPAN8 | Tetraspanin 8 | Cancer-related genes Predicted membrane proteins
| | | | | Tissue enhanced |
UCN3 | Urocortin 3 | Predicted secreted proteins
| | | | | Tissue enhanced |
UGT2A3 | UDP glucuronosyltransferase 2 family, polypeptide A3 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
UNC5CL | Unc-5 homolog C (C. elegans)-like | | | | | | Tissue enhanced |
UNC5D | Unc-5 homolog D (C. elegans) | Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
URAD | Ureidoimidazoline (2-oxo-4-hydroxy-4-carboxy-5-) decarboxylase | Enzymes
| | | | | Tissue enhanced |
VDR | Vitamin D (1,25- dihydroxyvitamin D3) receptor | Disease related genes FDA approved drug targets Nuclear receptors Transcription factors
| | | | | Tissue enhanced |
ZNF488 | Zinc finger protein 488 | Predicted secreted proteins
| | | | | Tissue enhanced |